Skip to main content
. 2017 Apr 7;8(30):49033–49043. doi: 10.18632/oncotarget.16931

Figure 4.

Figure 4

(A) Cell viability between the cisplatin-alone and co-treatment groups was not different following USP9X knockdown. NSCLC cell viability was determined using CCK-8. (B) USP9X knockdown led to increased inhibition of cell viability after cisplatin administration. CCK-8 was used to determine NSCLC cell viability. (C) Western blotting verified the efficiency of USP9X knockdown. *P < 0.05 vs. Control.